Just elected as member of board of directors of the German society of nuclear medicine as congress chair for the next 3 years. Proud and honored to serve the nuclear medicine community.

I am really happy to be one of the first authors of this article in JNM and have the oppurtunity to collect and analyse the data of patients received > 6 cycles of LuPSMA from different NM centers in Germany. Higlights: 🎯Favorable safety 🎯Maintained response

Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: A German Multicenter Study | Journal of Nuclear Medicine jnm.snmjournals.org/content/early/…

Important study: more than 6 cycles of Lu-177 PSMA is both and safe and efficacious. For patients who benefited from initial cycles, there is an urgent need to enable global access to more cycles of effective treatment.

SNMMI has been hard at work on the road! Yesterday, Drs. Frankis Almaguel, Gary Ulaner, and Michael Gorin shared the role of PSMA PET imaging for prostate cancer with 130+ urologists during a May 5 SNMMI Satellite Symposium at the American Urological Association Annual Meeting.

SAVE THE DATE for our next PSMA&Beyond Conference at UCLA on March 28-29 2025 ! #PSMA #theranostics Thomas Hope Jeremie Calais Johannes Czernin Prostate Cancer Foundation PCF Science

Great PSMA case discussion session led by Amir Iravani featuring Louise Emmett Thomas Hope Oliver Sartor, Eric Mittra SNMMI #snmmi24 Followed by the big opening session

This German multicenter retrospective information is very important: Extended therapy is safe and effective. ow.ly/v7r850ScqeC #NuclearMedicine #ProstateCancer #RPTherapy Matthias Eiber Ken Herrmann

JNM Researchers found that up to 13 cycles of therapy with Lu-177-PSMA increased the survival rate—particularly among the 61.3% of patients who paused their therapy for at least 4 months and then received a rechallenge dose.

177Lu-PSMA therapy in patients with prior Ra‑223 UroToday.com Kambiz Rahbar, MD Bayer Oncology Medical Novartis Cancer ✏️n=198 from 🇩🇪 & 🇮🇱 ✏️58%: received ≥4 life-prolonging Rx before 177Lu-PSMA ✏️After 177Lu-PSMA: - PSA30: 47% - PSA50: 37% - mOS: 12.0 mo ✏️mOS from Ra-223: 33.4 mo

Radium-223 goes 7.3 Exciting data presented by Silke Gillessen from PEACE-3 trial #ESMO2024

Final safety and efficacy analysis of RaLu: 177Lu-PSMA therapy in patients with prior Radium‑223. Presentation by Kambiz Rahbar, MD. #ESMO24 written coverage by Zach Klaassen > bit.ly/3MLY9N9 ESMO - Eur. Oncology

Great to meet world experts #APEX meeting on #prostatecancer OncoAlert Alicia Morgans, MD, MPH neal shore Dana-Farber Dana-Farber Lank Center for Genitourinary Oncology Renu Eapen Bayer Oncology Medical Rana McKay, MD, FASCO European Association of Urology (EAU) Paul Nguyen Prostate Cancer Foundation

Sequencing & combining radiopharmaceuticals: RaLu study shows lutetium-PSMA therapy is safe after radium treatment. PEACE-3 shows promise of radium-223+enzalutamide. Trials create more options for mCRPC. Oliver Sartor & Kambiz Rahbar, MD discuss on UroToday.com- tinyurl.com/3xrywkve

🚀 "The PRIMARY Score" hits a milestone—100 citations in JNM! 🎉 Kudos to Louise Emmett and our urology colleagues Declan Murphy Daniel Moon Matt Roberts + others for this impactful work jnm.snmjournals.org/content/jnumed… #PSMA #PRIMARYScore #ResearchImpact

Enza-P overall survival ASCO #GU25

LuCab Clinical Trial protocol now online JNM ANZUP #TheraP assessed Lu-177 PSMA-617 versus cabazitaxel LuCab assesses Lu-177 PSMA-617 in combination with cabazitaxel jnm.snmjournals.org/content/early/… Congrats Louise Kostos, our medical oncology PhD leading this

Twenty cycles (that's right 20) of Lutetium-177 PSMA-617 for metastatic castration-resistant cancer!! Check our case report just published in JNM jnm.snmjournals.org/content/early/… Current randomized controlled data demonstrate the safety and efficacy of 6 cycles of

Exciting 177Lu-PSMA-617 has been approved by the FDA for use prior to chemotherapy based on the PSMAfore results. Perfect timing, during day 1 of the PSMA and Beyond Conference! bit.ly/42lfdlz

bmccancer.biomedcentral.com/articles/10.11…